Haleon plc (HLN)
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic
Haleon plc is a Healthcare company with a market capitalization of $40.72B, a trailing P/E ratio of 18.9, and a dividend yield of 2.09%.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025 · in GBP
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | April 29, 2026 | $0.00 | $0.12 | -100.0% |
| Q3 2025 | October 30, 2025 | $0.12 | $0.13 | -2.6% |
| Q2 2025 | August 7, 2025 | $0.09 | $0.11 | -15.6% |
| Q1 2025 | April 30, 2025 | $0.13 | $0.00 | — |
| Q4 2024 | February 27, 2025 | $0.03 | $0.10 | -71.0% |
| Q3 2024 | October 31, 2024 | $0.12 | $0.11 | +9.1% |
Other Drug Manufacturers - Specialty & Generic Stocks
Frequently Asked Questions
What is Haleon plc's market cap?
As of June 29, 2026, Haleon plc (HLN) has a market capitalization of $40.72B.
What is Haleon plc's P/E ratio?
Haleon plc trades at a trailing price-to-earnings (P/E) ratio of 18.9. Its forward P/E is 17.5.
Does Haleon plc pay a dividend?
Yes — Haleon plc pays a dividend yielding 2.09%, an annual payout of $0.07 per share.
What sector is HLN in?
Haleon plc is in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry.
What was Haleon plc's revenue?
In its latest reported fiscal year (ending December 31, 2025), Haleon plc reported revenue of 10.79B GBP and net income of 1.63B GBP.
Ask your own questions about HLN
Try mrmarket.ai freeData as of June 29, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.